FORM 4
☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person
   Downing Cristal N
   (Last) (First) (Middle)
   MERCK & CO., INC., 126 EAST LINCOLN AVENUE
   RAHWAY, NJ 07065

2. Issuer Name and Ticker or Trading Symbol
   Merck & Co., Inc. [ MRK ]

3. Date of Earliest Transaction (MM/DD/YYYY)
   10/31/2023

4. If Amendment, Date Original Filed (MM/DD/YYYY)

5. Relationship of Reporting Person(s) to Issuer
   (Check all applicable)
     __ Director
     __ 10% Owner
     __ Officer (give title below)
     __ Other (specify below)
     ___ Chief Comm. & Public Afrs Ofcr

6. Individual or Joint/Group Filing (Check Applicable Line)
   __ Form filed by One Reporting Person
   ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Title of Security</th>
<th>Trans. Date</th>
<th>Trans. Code</th>
<th>Securities Acquired (A) or Disposed of (D)</th>
<th>Amount of Securities Beneficially Owned Following Reported Transaction(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Restricted Stock Unit</td>
<td>10/31/2023</td>
<td>A</td>
<td>11,685</td>
<td>11,685</td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>Title of Derivative Security</th>
<th>Conversion or Exercise Price of Derivative Security</th>
<th>Trans. Date</th>
<th>Trans. Code</th>
<th>Number of Derivative Securities Acquired (A) or Disposed of (D)</th>
<th>Date Exercisable</th>
<th>Expiration Date</th>
<th>Title</th>
<th>Amount or Number of Shares</th>
</tr>
</thead>
<tbody>
<tr>
<td>Restricted Stock Unit</td>
<td></td>
<td>10/31/2023</td>
<td>A</td>
<td>11,685</td>
<td>10/31/2026</td>
<td>10/31/2026</td>
<td>Common Stock</td>
<td>11,685</td>
</tr>
</tbody>
</table>

Common Stock
11,685
0
11,685
D

Explanation of Responses:
(1) Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
(2) These restricted stock units vest in full and are distributed as shares of Merck & Co., Inc. common stock on 10/31/2026.

Reporting Owners

<table>
<thead>
<tr>
<th>Reporting Owner Name / Address</th>
<th>Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>Downing Cristal N</td>
<td>Director</td>
</tr>
<tr>
<td></td>
<td>10% Owner</td>
</tr>
<tr>
<td></td>
<td>Officer</td>
</tr>
<tr>
<td>MERCK &amp; CO., INC.</td>
<td>Other</td>
</tr>
<tr>
<td>126 EAST LINCOLN AVENUE</td>
<td></td>
</tr>
<tr>
<td>RAHWAY, NJ 07065</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chief Comm. &amp; Public Afrs Ofcr</td>
</tr>
</tbody>
</table>

Signatures

/s/ Kelly E. W. Grez as Attorney-in-Fact for Cristal N. Downing

Signature of Reporting Person

11/1/2023

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
If the form is filed by more than one reporting person, see Instruction 4(b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.